Vanda Pharmaceuticals Announces FDA Approval of BYSANTI(TM) (milsaperidone) for the treatment of Bipolar I Disorder and Schizophrenia - A New Chemical Entity Opening New Horizons in Psychiatric Innovation

Stock Information for Vanda Pharmaceuticals Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Vanda Pharmaceuticals Inc.

Vanda Pharmaceuticals Announces FDA Approval of NEREUS(TM) (tradipitant) for the Prevention of Vomiting Induced by Motion: A Historic Scientific Milestone in the Prevention of Motion Sickness
Vanda Announces Submission of Biologics License Application to the FDA for Imsidolimab for the Treatment of Generalized Pustular Psoriasis
Vanda Pharmaceuticals Announces Participation in the J.P. Morgan Healthcare Conference
FDA Lifts Partial Clinical Hold on Tradipitant for Motion Sickness
Vanda Pharmaceuticals Provides Regulatory Update on Tradipitant for Motion Sickness
Vanda Pharmaceuticals Reports Positive Results for Tradipitant in Preventing GLP-1 Induced Nausea and Vomiting
Vanda Pharmaceuticals Announces Participation in the Stifel 2025 Healthcare Conference
Vanda Pharmaceuticals Reports Third Quarter 2025 Financial Results

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.